InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies
Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...
HKG: 9969
InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production
Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...
InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial
Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study...
InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA
China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...